Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(166 products)
- Bcr-Abl(117 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(86 products)
- Fibroblast Growth Factor Receptor (FGFR)(178 products)
- JAK(244 products)
- PDGFR(127 products)
- RAAS(86 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(56 products)
- VDA(2 products)
- VEGFR(239 products)
Show 6 more subcategories
Found 2344 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
SA-VA
SA-VA, an intracellular self-assembled PROTAC featuring azide and alkyne groups, selectively degrades VEGFR-2 and EphB4 proteins within U87 cells.Formula:C50H53ClF3N11O7SPurity:98%Color and Shape:SolidMolecular weight:1044.54FW-1
FW-1 is a type I inhibitor of FLT3, with an IC50 of approximately 1 μM. It exhibits cytotoxic effects in FLT3-mutant AML cells, causes cell cycle arrest at the G0/G1 phase, and induces apoptosis in MV4-11 and MOLM-13 cells.
Formula:C24H27N7OColor and Shape:SolidMolecular weight:429.517VEGFR-2-IN-66
VEGFR-2-IN-66 (Compound 6) is an orally active VEGFR-2 inhibitor with an IC50 of 0.509 µM and an IC50 value of 7.48 μM for inhibiting MCF-7 cell proliferation. Its anticancer activity is exerted through cell cycle arrest, induction of apoptosis (Apoptosis), and modulation of gene expression, making it suitable for breast cancer research.Color and Shape:Odour SolidhCA/VEGFR-2-IN-3
hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide with potential as a dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2.Formula:C24H28N6O6SPurity:98%Color and Shape:SolidMolecular weight:528.58EGFR/BRAFV600E-IN-3
EGFR/BRAFV600E-IN-3 is an inhibitor targeting EGFR, BRAFV600E, and EGFRT790M with IC50 values of 57 nM, 68 nM, and 9.70 nM, respectively.Formula:C25H18N4O3Purity:98%Color and Shape:SolidMolecular weight:422.44FAK-IN-27
FAK-IN-27 (compound 8A) is a potent and selective inhibitor of FAK, with an IC50 of 4.968 nM. It effectively inhibits the proliferation of H1299 cells, with an IC50 of 0.28 μM, and is applicable for research in non-small cell lung cancer (NSCLC).Formula:C32H28ClN5O6Color and Shape:SolidMolecular weight:613.17281SJ1008030
CAS:SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.
Formula:C42H43N13O7SColor and Shape:SolidMolecular weight:873.94FLT3 Ligand-Linker Conjugate 1
CAS:FLT3 Ligand-Linker Conjugate 1 consists of an FLT3 ligand and a PROTAC linker that can recruit E3 ligase VHL. This conjugate is useful for synthesizing PROTAC RSS0680, a bifunctional compound designed for targeted protein degradation of kinases.Formula:C29H34N6O4S2Color and Shape:SolidMolecular weight:594.748LH168
LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.Formula:C29H31F3N6O2SColor and Shape:SolidMolecular weight:584.66BRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formula:C23H23ClFN7O2Color and Shape:SolidMolecular weight:483.93EGFR/VEGFR2-IN-5
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.Formula:C17H15N7O5SColor and Shape:SolidMolecular weight:429.41EGFR T790M/L858R-IN-9
EGFRT790M/L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R/T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R/T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M/L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.Formula:C26H27N7O3SColor and Shape:SolidMolecular weight:517.603EGFR/BRAFV600E-IN-4
EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.Formula:C22H16N4OSColor and Shape:SolidMolecular weight:384.45TYVPANASL TFA
TYVPANASL TFA, a nine-amino-acid MHC I-binding CD8 T-cell epitope derived from HER2/neu, is utilized in the formulation of J-LEAPS vaccines [1].Color and Shape:Odour SolidFGFRs-IN-1
FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.Formula:C28H26Cl2N4O3Color and Shape:SolidMolecular weight:537.44JAK3-IN-14
CAS:JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.Formula:C18H13N3OPurity:98.29%Color and Shape:SoildMolecular weight:287.32Ref: TM-T67754
1mg167.00€5mg409.00€10mg595.00€25mg888.00€50mg1,234.00€100mg1,665.00€1mL*10mM (DMSO)358.00€MY-1576
MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.Formula:C25H29ClN8O2Color and Shape:SolidMolecular weight:509HER2-IN-14
CAS:HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.Formula:C26H23ClF2N8O3Color and Shape:SolidMolecular weight:568.96Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Purity:98%Color and Shape:Odour SolidFGFR1/VEGFR2-IN-1
FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1].
Formula:C26H27N4O6PPurity:98%Color and Shape:SolidMolecular weight:522.49Disitamab vedotin
CAS:Disitamab vedotin (RC-48) is a HER2-targeting ADC with MMAE, effective in HER2-expressing gastric cancer.Purity:95.00% - 98%Color and Shape:LiquidMolecular weight:149 kDaMET/PDGFRA-IN-1
MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.Formula:C26H23N7OPurity:98%Color and Shape:SolidMolecular weight:449.51Anti-β Klotho Antibody (Fazpilodemab)
CAS:Fazpilodemab (BFKB8488A) is a humanized bispecific antibody that targets and activates the Klotho β and fibroblast growth factor receptor 1c receptor complex.Color and Shape:LiquidMolecular weight:146 kDaU3-1784
U3-1784 is a humanized monoclonal antibody targeting CD334, with anti-cancer activity, used in liver cancer research.Color and Shape:LiquidMolecular weight:143.22 kDaAmuvatinib hydrochloride
CAS:Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.Formula:C23H22ClN5O3SPurity:98%Color and Shape:SolidMolecular weight:483.97SIAIS100
SIAIS100, a potent BCR-ABL PROTAC degrader, demonstrates a DC50 value of 2.7 nM, highlighting its efficacy.Formula:C44H50ClF2N9O5SColor and Shape:SolidMolecular weight:890.44ALK-IN-29
ALK-IN-29 (compound 4c) exhibits inhibitory effects on tyrosine protein kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, displaying a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is applicable in cancer research.Formula:C29H32FN3OColor and Shape:SolidMolecular weight:457.58Itacitinib adipate
CAS:Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.Formula:C32H33F4N9O5Color and Shape:SolidMolecular weight:699.66GW2974
CAS:GW2974, Oral EGFR/ErbB2 dual inhibitor, inhibits glioblastoma multiforme (GBM) cell invasion and tumor growth.Formula:C23H21N7Color and Shape:SolidMolecular weight:395.46Lestaurtinib
CAS:Lestaurtinib (CEP 701) is a FLT3 inhibitor that inhibits the phosphorylation of RPTKs and can be used to study leukemia.Formula:C26H21N3O4Purity:99.17%Color and Shape:Off-White SolidMolecular weight:439.46BI-3663
CAS:BI-3663 is a selective PTK2/FAK PROTAC with cereblon ligands, degrading PTK2 (IC50: 18 nM), and shows anti-cancer properties.Formula:C44H42F3N7O12Purity:98%Color and Shape:SolidMolecular weight:917.84DTP3
CAS:DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.Formula:C26H35N7O5Color and Shape:SolidMolecular weight:525.6PND-1186 hydrochloride
CAS:PND-1186 hydrochloride (VS-4718 hydrochloride) is a highly specific, reversible and potent inhibitor of FAK (IC50: 1.5 nM), which can selectively induceFormula:C25H27ClF3N5O3Color and Shape:SolidMolecular weight:537.97Naphazoline nitrate
CAS:Naphazoline nitrate: α1-adrenergic agonist, induces autophagy, necrosis in cancer cells, inhibits differentiation, treats congestion and eye issues.Formula:C14H15N3O3Purity:98%Color and Shape:White Crystalline Powder White SolidMolecular weight:273.29CHZ868
CAS:CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.Formula:C22H19F2N5O2Purity:99.38%Color and Shape:SolidMolecular weight:423.42Sunitinib-d10
CAS:Sunitinib D10, a deuterium-enriched version, inhibits VEGFR2 and PDGFRβ tyrosine kinases (IC50: 80 nM/2 nM).Formula:C22H27FN4O2Purity:98%Color and Shape:SolidMolecular weight:408.54Flurandrenolide
CAS:Flurandrenolide is a corticosteroid with anti-inflammatory effects that activates EGFR (EC50=23 nM).Formula:C24H33FO6Color and Shape:Crystals From Acetone + Hexane SolidMolecular weight:436.51BI-4142
CAS:BI-4142 is a HER2 inhibitor that inhibits cancer cell proliferation, suppresses her2-dependent cell lines and inhibits downstream signalling.Formula:C28H27N9O2Purity:97.21% - 98.09%Color and Shape:SolidMolecular weight:521.57Ref: TM-T63643
1mg57.00€5mg120.00€10mg177.00€25mg356.00€50mg537.00€100mg803.00€200mg1,341.00€1mL*10mM (DMSO)138.00€BPR1K871
CAS:BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values ofFormula:C25H28ClN7O2SColor and Shape:SolidMolecular weight:526.05IBT6A hydrochloride
CAS:IBT6A hydrochloride: Ibrutinib impurity, Btk inhibitor IC50: 0.5 nM, used in dimer/adduct synthesis.Formula:C22H23ClN6OColor and Shape:SolidMolecular weight:422.91Erlotinib-d6 hydrochloride
CAS:Erlotinib Hydrochloride inhibits purified EGFR kinase with an IC50 of 2 nM. Erlotinib D6 hydrochloride a deuterium labeled Erlotinib Hydrochloride.Formula:C22H24ClN3O4Purity:98%Color and Shape:SolidMolecular weight:435.93A-770041
CAS:A-770041 is an Lck inhibitor, YZ inhibits the production of IL-2 stimulated by concanavalin A in whole blood, and can prevent cardiac allograft rejection.Formula:C34H39N9O3Purity:99.23% - 99.86%Color and Shape:SolidMolecular weight:621.73Ref: TM-T14074
2mg70.00€5mg104.00€10mg170.00€25mg384.00€50mg652.00€100mg1,018.00€200mg1,350.00€1mL*10mM (DMSO)142.00€Osimertinib dimesylate
CAS:Osimertinib dimesylate is an irreversible and mutant selective EGFR inhibitor (IC50s: 12 and 1 nM against EGFR L858R and EGFR L858R/T790M).Formula:C30H41N7O8S2Purity:98%Color and Shape:SolidMolecular weight:691.82Ponatinib-d8
CAS:Ponatinib D8 is a deuterium-enriched, oral multi-kinase inhibitor (Abl, PDGFRα, VEGFR2, FGFR1, Src; IC50s: 0.37-5.4 nM).Formula:C29H27F3N6OPurity:98%Color and Shape:SolidMolecular weight:540.61Lanraplenib succinate
CAS:Lanraplenib succinate is an oral SYK inhibitor (IC50=9.5 nM) that doesn't extend BT, targeting GPVI in platelets for inflammation treatment.Formula:C58H68N18O14Color and Shape:SolidMolecular weight:1241.294Mavelertinib
CAS:Mavelertinib (PF-06747775) is an EGFR tyrosine kinase (EGFR TKI) inhibitor that inhibits T790M/L858R and can be used to study tumours.Formula:C18H22FN9O2Purity:99.89%Color and Shape:SolidMolecular weight:415.42Nilotinib-d6
CAS:Nilotinib D6 is a deuterium labeled Nilotinib which is an orally available inhibitor of Bcr-Abl tyrosine kinase ,and with antineoplastic activity.Formula:C28H22F3N7OPurity:98%Color and Shape:SolidMolecular weight:535.55SU11652
CAS:SU11652 is an effective and competitive receptor tyrosine kinase (RTK) inhibitor, including VEGFR, FGFR, PDGFR, and Kit.Formula:C22H27ClN4O2Purity:99.14%Color and Shape:SolidMolecular weight:414.93Poseltinib
CAS:Poseltinib is an oral, irreversible BTK inhibitor (IC50 1.95 nM) with higher selectivity over BMX, TEC, and TXK, blocking BCR, FcR, and TLR signaling.Formula:C26H26N6O3Purity:99.98%Color and Shape:SolidMolecular weight:470.52Ref: TM-T4413
2mg34.00€5mg49.00€10mg75.00€25mg146.00€50mg260.00€100mg409.00€200mg590.00€1mL*10mM (DMSO)50.00€Tucatinib hemiethanolate
CAS:Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.Formula:C54H54N16O5Purity:99.76%Color and Shape:SolidMolecular weight:1007.11
